Molecule May Be a Marker for Deadly Prostate Cancer
Improved diagnostic techniques for prostate cancer, the most common cancer among American men, have led to a threefold increase in the rate of diagnosis since 1988. But that presents physicians with a dilemma: Many of these early cancers are
Improved diagnostic techniques for prostate cancer, the most commoncancer among American men, have led to a threefold increase in the rateof diagnosis since 1988. But that presents physicians with a dilemma: Manyof these early cancers are relatively benign and do not warrant aggressiveintervention. How is the physician to tell which cancers will go on todevelop life-threatening metastases?
Harvard researchers may have found a way. In the December issue of NatureMedicine, a research team led by Lere Bao, instructor in surgery atChildren's Hospital, Boston, reports the identification and genetic descriptionof a telltale molecule: thymosin B15, a protein involved in cell motility.The researchers found that, in an animal model, the protein gears up thecancer cell's ability to move around the body, which is part of the progressionof metastasis. They also note that thymosin B15 is not expressed in normalor benign human prostate cells but appears at high levels in human prostatecancers with high metastatic potential.
Apparently, the protein helps the cancer cell break free of its attachmentsto neighboring cells and surrounding tissue, allowing it to course throughthe body and form secondary tumors elsewhere.
Other authors are Massimo Loda and Robert Stewart, Beth Israel DeaconessMedical Center; Paul A. Janmey, Brigham and Women's Hospital; and BelaAnand-Apte and Bruce R. Zetter, Children's Hospital.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
